http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009067520-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d8526b670575e676e6f846d4f4f5cf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bd7a45a343acd10e3f5d8775dda2157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_773bc1332922734a8980808b01910df9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2f853bac4c430c7f6581e137175b5e2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2008-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5a67796aa0a5ee3985f12f74159a0af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24fa178ec27621686ebba44e478b7fe0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_790d88c189a4cebe4b48e9dd86ac89fe |
| publicationDate | 2009-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2009067520-A2 |
| titleOfInvention | Peptides specific for hepatocellular carcinoma cells and applications thereof |
| abstract | Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102732522-A |
| priorityDate | 2007-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 205.